Dr. Keishi Nihira received his Ph.D. in Science from Tokyo Medical and Dental University Japan in 2011. During graduate school, he studied the post-translational modification of proteins, such as phosphorylation, related to intracellular signaling of proliferation, apoptosis and cell cycle in cancer cells. After graduation, he entered Kowa Company, Ltd. Here Dr. Nihira arranged a method for high throughput screening and performed this system to find compounds for therapeutics.
Dr. Nihira joined the Center for Interdisciplinary Cardiovascular Sciences in April 2014. He is researching macrophage biology to identify therapeutic targets.